Immune Checkpoint Inhibitors and RAS–ERK Pathway-Targeted Drugs as Combined Therapy for the Treatment of Melanoma
Metastatic melanoma is a highly immunogenic tumor with very poor survival rates due to immune system escape-mechanisms. Immune checkpoint inhibitors (ICIs) targeting the cytotoxic T-lymphocyte-associated protein 4 (CTLA4) and the programmed death-1 (PD1) receptors, are being used to impede immune ev...
Main Authors: | Marta Morante, Atanasio Pandiella, Piero Crespo, Ana Herrero |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-10-01
|
Series: | Biomolecules |
Subjects: | |
Online Access: | https://www.mdpi.com/2218-273X/12/11/1562 |
Similar Items
-
RAS Dimers: The Novice Couple at the RAS-ERK Pathway Ball
by: Ana Herrero, et al.
Published: (2021-09-01) -
Envoplakin Inhibits Macrophage Polarization by Altering the Inflammatory Tumor Microenvironment of Melanoma Through the RAS / ERK Signaling Pathway
by: Cai W, et al.
Published: (2024-03-01) -
Sensitivity and Resistance of Oncogenic RAS-Driven Tumors to Dual MEK and ERK Inhibition
by: Antonella Catalano, et al.
Published: (2021-04-01) -
Update on Immune Checkpoint Inhibitors for Conjunctival Melanoma
by: Ho-Seok Sa, et al.
Published: (2022-08-01) -
Impairment of cocaine-mediated behaviours in mice by clinically relevant Ras-ERK inhibitors
by: Alessandro Papale, et al.
Published: (2016-08-01)